Life Sciences

Subscribe for Updates

RepliCel

Show printable version of 'RepliCel' item in a New Window

Berkley Renewables holds 91,812 of the issued and outstanding shares of RepliCel Life Sciences Inc., with the option to acquire more shares. RepliCel Life Sciences specializes in autologous* cell therapy technologies. The company's foundation is built on its core understanding of the unique biological function of hair follicle cells. Patents for the technology have been granted in the United States, Australia, Japan and the European Union with further jurisdictions pending.

The company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company is also developing a proprietary, next-generation injection device (RCI) for optimal clinical delivery. Each condition is related to a deficit of a specific cell type which management believes is critical to the restoration of normal function..

RepliCel's RCH-01 Hair Regeneration treatment is now under clinical investigation at Tokyo Medical University Hospital and Toho University Ohasi Medical Center. The study is being financed by Shiseido Company, Limited.

In late March, 2017, RepliCel reported compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel's type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis.

The clinical trial met its goal of establishing a complete safety profile at 6 months and showed no serious adverse events related to the study treatment or injection procedure.

Additionally, each of the treated participants, all of whom suffered chronic tendon pain and loss of function over an extended period of time with no recovery from standard treatments, showed numerous clinically important improvements by various measures including tendon composition, blood supply, physical function and pain sensation.

Just a week later, RepliCel reported statistically and clinically significant results from the company's phase 1 skin trial.

For more information, please visit www.replicel.com

*Using a patient's own cells